{
    "clinical_study": {
        "@rank": "157985", 
        "acronym": "BLOC-FEMPOP", 
        "arm_group": [
            {
                "arm_group_label": "NaC1", 
                "arm_group_type": "Other", 
                "description": "The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption."
            }, 
            {
                "arm_group_label": "Levobupivacaine + clonidine", 
                "arm_group_type": "Other", 
                "description": "The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the\n      benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and\n      clonidine in a single dose, performed before induction of general anaesthesia, on analgesia\n      postoperatively assessed by morphine consumption.\n\n      Applied to the patient at the beginning of general anesthesia, this technique could allow\n      one hand, to reduce the need for opiates, on the other hand - due to anesthetized limb\n      vasodilation - to improve tissue perfusion downstream."
        }, 
        "brief_title": "Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "- Patients to Benefit a Planned Femoropopliteal Bypass Through PAOD (Peripheral Arterial Occlusive Disease) Stage II or III.", 
        "condition_browse": {
            "mesh_term": [
                "Arterial Occlusive Diseases", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "Course of the study Visit 1 (J-15 J-1): Pre-inclusion During a follow-up visit usual\n      pathology, the doctor will propose to the patient to participate in the protocol.\n      Information Form will be given to the patient to be read at home to maintain a sufficient\n      time for reflection.\n\n      Visit 2 (J-1): Pre-anesthetic, the eve of the intervention:\n\n      During the pre-anesthetic consultation routine, the doctor will check the informed consent\n      and then note the following information on the case report form: age, height, weight, sex of\n      the patient.\n\n      Visit 3 (J0): Surgery One hour before surgery the patient will receive premedication with\n      Hydroxyzine (Atarax \u00ae).\n\n      Then the anesthetic team install patient in monitoring room so that the test products are\n      administered according to the double-blind randomization schedule prepared in advance. When\n      the block is made, the patient is brought into the operating room for general anesthesia and\n      surgery.\n\n      By the end of surgery, the following data will be collected in the case report form :\n\n        -  Vital parameters (heart rate, blood pressure, PetCO2, SpO2) every 10 minutes and\n           incidents.\n\n        -  Time of injection tested products and time of induction of general anesthesia.\n\n        -  Major Surgical times : incision, venous sampling when indicated, heparin bolus,\n           clamping the superficial femoral artery, arterial unclamping, skin closure.\n\n        -  Duration of operation (in minutes from the incision to skin closure).\n\n        -  Intraoperative sufentanil consumption (micrograms).\n\n      Monitoring and medical care in Post Anaesthesia Carry Unit (PACU):\n\n      After surgery, the patient will be conducted in PACU. He will benefit from routine\n      monitoring of vital parameters (heart rate, blood pressure, respiratory rate and SpO2).\n\n      Then patient extubation, according to usual criteria, will be performed: extubation of the\n      patient is the H0, when all the time measurement start.\n\n      - H0: Extubation Morphine consumption will be measured continuously during the 72 first\n      postoperative hours.\n\n      rSO2 be measured by NIRS during the first 12 first postoperative hours.\n\n        -  H0 +30 min: rating of pain (simple numerical scale) + sedation score\n\n        -  H0 +60 min: rating of pain + sedation score\n\n        -  H0 +90 min: rating of pain\n\n        -  H0 +120 min: rating of pain + sedation score\n\n        -  H0+4h: rating of pain + sedation score\n\n        -  H0+8h: rating of pain + sedation score\n\n        -  H0+12h: rating of pain\n\n        -  H0+16h: rating of pain + sedation score\n\n        -  H0+20h: rating of pain\n\n        -  H0+24h: rating of pain + sedation score + morphine consumption with PCA and number of\n           requests over the last 24 hours.\n\n        -  H0+32h: rating of pain\n\n        -  H0+40h: rating of pain\n\n        -  H0+48h: rating of pain + morphine consumption with PCA and number of requests over the\n           last 24 hours.\n\n        -  H0+56h: rating of pain\n\n        -  H0+64h: rating of pain\n\n        -  H0+72h: rating of pain + morphine consumption with PCA and number of requests over the\n           last 24 hours.\n\n        -  At the end of PACU: rating of pain + sedation score\n\n      Thereafter, recovery time of ambulation will be registered and duration of hospital stay,\n      rate of reoperation within 30 post-operative days and 30-day survival.\n\n      Adverse events will be collected to have information about hemodynamic tolerance of the\n      products.\n\n      The patient is then monitored in the usual care of the disease."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients to benefit a planned femoropopliteal bypass through PAOD stage II or III.\n\n          -  Aged 18 to 80 years.\n\n          -  Having given their consent.\n\n          -  Affiliated with a social security scheme.\n\n        Exclusion Criteria:\n\n          -  Patients with PAOD stage I or IV.\n\n          -  Chronic respiratory failure.\n\n          -  Severe coronary insufficiency.\n\n          -  Renal or hepatic impairment.\n\n          -  Patients with chronic pain or preoperative long-term opioid treatment.\n\n          -  Patients with cognitive impairment (judged by the investigator) that may interfere\n             with:\n\n               -  informed consent,\n\n               -  the collection of endpoints,\n\n               -  the use of patient-controlled analgesia.\n\n          -  Severe abnormality of hemostasis (platelets <80.000 / ml) and / or of coagulation (PT\n             <50%, factor V <50%).\n\n          -  Patients with diabetes mellitus and / or diabetic neuropathy.\n\n          -  Pregnant or nursing women, women of childbearing age.\n\n          -  Refusal of the protocol.\n\n          -  Minor or major protected patients.\n\n          -  Contraindications to one of the following products:\n\n        levobupivacaine, clonidine, morphine, paracetamol, nefopam.\n\n        - Patients with a contra-indication to the administration of sufentanil: hypersensitivity\n        to any component, hypersensitivity to morphine, hypersensitivity to opiates."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785693", 
            "org_study_id": "CHU-129", 
            "secondary_id": "2012-002123-15"
        }, 
        "intervention": {
            "arm_group_label": [
                "NaC1", 
                "Levobupivacaine + clonidine"
            ], 
            "intervention_name": "levobupivacaine, clonidine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Anesthetics", 
                "Levobupivacaine", 
                "Bupivacaine", 
                "Clonidine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nerve block", 
            "Femoropopliteal bypass", 
            "Postoperative analgesia", 
            "Peripheral circulation", 
            "Levobupivacaine", 
            "Clonidine", 
            "Pain"
        ], 
        "lastchanged_date": "February 5, 2013", 
        "location": {
            "contact": {
                "email": "placarin@chu-clermontferrand.fr", 
                "last_name": "Patrick LACARIN", 
                "phone": "04 73 75 11 95"
            }, 
            "facility": {
                "address": {
                    "city": "Clermont-Ferrand", 
                    "country": "France", 
                    "zip": "63003"
                }, 
                "name": "CHU Clermont-Ferrand"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream.", 
        "overall_contact": {
            "email": "placarin@chu-clermontferrand.fr", 
            "last_name": "Patrick LACARIN", 
            "phone": "04 73 75 11 95"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Clermont-Ferrand", 
            "last_name": "Philippe JOUVE", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "total morphine consumption", 
            "safety_issue": "Yes", 
            "time_frame": "between hour 0 and hour 0+24h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785693"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "total morphine consumption", 
                "safety_issue": "Yes", 
                "time_frame": "between Hour 0 and Hour 0+72h"
            }, 
            {
                "measure": "pain score at rest", 
                "safety_issue": "Yes", 
                "time_frame": "30, 60, 90 and 120 minutes after extubation"
            }, 
            {
                "measure": "pain score", 
                "safety_issue": "Yes", 
                "time_frame": "every 4 hours during the 24 first post-operative hours"
            }, 
            {
                "measure": "pain score", 
                "safety_issue": "Yes", 
                "time_frame": "every 8 hours during the next post-opeartive 48 hours"
            }, 
            {
                "measure": "total sufentanil consumption", 
                "safety_issue": "Yes", 
                "time_frame": "between induction and extubation"
            }, 
            {
                "measure": "rate of reoperation", 
                "safety_issue": "Yes", 
                "time_frame": "between day1 and day30"
            }, 
            {
                "measure": "mortality rate", 
                "safety_issue": "Yes", 
                "time_frame": "at day 30"
            }, 
            {
                "measure": "sedation score", 
                "safety_issue": "Yes", 
                "time_frame": "at hour0+30mn, at hour 0+1h, at hour 0+2h, at H0+4h, at hour 0+8h, at H0+16h, at hour 0+24h"
            }, 
            {
                "measure": "Hemodynamic tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "between day 1 and day 30"
            }, 
            {
                "measure": "nausea", 
                "safety_issue": "Yes", 
                "time_frame": "between day 1 and day 30"
            }, 
            {
                "measure": "vomiting", 
                "safety_issue": "Yes", 
                "time_frame": "between day 1 and day 30"
            }, 
            {
                "measure": "Bleeding score", 
                "safety_issue": "Yes", 
                "time_frame": "between hour 0 and hour 0+24h"
            }
        ], 
        "source": "University Hospital, Clermont-Ferrand", 
        "sponsors": {
            "collaborator": {
                "agency": "ARAMU Association Loi 1901 (Anesth\u00e9sie, R\u00e9animation, Analg\u00e9sie, M\u00e9decine d\u2019Urgence)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Clermont-Ferrand", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}